4-[(1,1-二甲基丙基-2-基)氧基]苯甲腈 | 33143-92-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-[(1,1-二甲基丙基-2-基)氧基]苯甲腈
• 英文名称: 3-(4-cyanophenoxy)-3-methylbut-1-yne
• 英文别名: 4-[(1,1-Dimethyl-2-propynyl)oxy]benzonitrile；4-[(1,1-Dimethylprop-2-ynyl)oxy]benzonitrile；4-(2-methylbut-3-yn-2-yloxy)benzonitrile
• CAS: 33143-92-9
• 化学式: C₁₂H₁₁NO
• 分子量: 185.225
• InChiKey: BJBUSSBIFHSXBR-UHFFFAOYSA-N

物化性质

• 熔点：
  30 °C
• 沸点：
  313.4±22.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2926909090
• 危险品运输编号：
  UN 3276

SDS

Name:	4-[(1 1-Dimethylprop-2-ynyl)oxy]benzonitrile 97% Material Safety Data Sheet
Synonym:	3-(4-Cyanophenoxy)-3-methylbut-1-yn
CAS:	33143-92-9

Section 1 - Chemical Product MSDS Name:4-[(1 1-Dimethylprop-2-ynyl)oxy]benzonitrile 97% Material Safety Data Sheet
Synonym:3-(4-Cyanophenoxy)-3-methylbut-1-yn

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
33143-92-9	4-[(1,1-Dimethylprop-2-ynyl)oxy]benzon	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 33143-92-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 30 - 32 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H11NO
Molecular Weight: 185.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, halogenated agents, halogens.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 33143-92-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-[(1,1-Dimethylprop-2-ynyl)oxy]benzonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 33143-92-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 33143-92-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 33143-92-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-[(1,1-二甲基丙基-2-基)氧基]苯甲腈 在 manganese(II) triflate 、 N1,N2-Bis(2-((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)phenyl)benzene-1,2-diamine 、 双氧水 、 sodium hydride 、 溶剂黄146 作用下， 以 二甲基亚砜 、 N,N-二甲基苯胺 、 乙腈 为溶剂， 反应 8.0h， 生成 左色满卡林
  参考文献：
  名称：

  Asymmetric Epoxidation of Alkenes Catalyzed by a Porphyrin-Inspired Manganese Complex

  摘要：

  A novel strategy for catalytic asymmetric epoxidation of a wide variety of olefins by a porphyrin-inspired chiral manganese complex using H2O2 as a terminal oxidant in excellent yield with up to greater than 99% ee has been successfully developed.

  DOI：

  10.1021/ol401812h
• 作为产物：
  描述：

  4-羟基苯甲腈 在 potassium carbonate 、 potassium iodide 作用下， 反应 18.0h， 以0.77 g的产率得到4-[(1,1-二甲基丙基-2-基)氧基]苯甲腈
  参考文献：
  名称：

  亚胺盐介导的色酮的不对称环氧化：软体动物和（3 S，4 R）-反式-3,4-二羟基-3,4-二氢软体动物的合成

  摘要：

  亚胺盐催化剂在非水条件下介导的色酮的有机催化不对称环氧化提供了高达99％的ee。相反，在水性条件下的反应可以形成相应的二醇产物，其ee s高达71％。该方法已用于合成东非药用植物代谢产物（3 S，4 R）-反式-3,4-二羟基-3,4-二氢软糖。

  DOI：

  10.1016/j.tet.2016.10.070
• 作为试剂：
  描述：

  1,1-dimethyl-2-propynyl trifluoroacetate 、 4-羟基苯甲腈 在 ice 、 水 、 甲苯 、 盐酸 、 sodium hydroxide 、 碳酸氢钠 、 Brine 、 magnesium sulfate 、 4-[(1,1-二甲基丙基-2-基)氧基]苯甲腈 、 crude material 作用下， 以 水 为溶剂， 反应 2.08h， 以afforded the title compound as a colorless, low melting solid (8.93 g)的产率得到4-[(1,1-二甲基丙基-2-基)氧基]苯甲腈
  参考文献：
  名称：

  Process for the preparation of intermediates useful in the preparation

  摘要：

  一种制备公式##STR1##中a、b、c、R.sub.1、R.sub.2和R.sub.3如本文所定义的化合物的方法，包括用公式##STR2##中的苯酚与公式##STR3##中的乙炔烷基化反应的步骤，其中X为氯、溴、--OC（O）--R.sub.5，其中R.sub.5为烷基、芳基或取代芳基；或者--OCO.sub.2 R.sub.6，其中R.sub.6为烷基或##STR4##，在存在少量的铜盐的催化下。公式I的化合物是制备吡喃基氰脲衍生物的中间体。

  公开号：

  US05463059A1

文献信息

• Benzopyran derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04971982A1

  公开（公告）日：1990-11-20

  Compounds of the formula ##STR1## wherein R.sup.1 is hydrogen, halogen, trifluoromethyl, nitro, cyano, lower alkyl, lower alkoxycarbonyl, lower alkylthio, lower alkylsulphonyl, lower alkanoyl, aroyl, carbamoyl, mono(lower alkyl)carbamoyl or di(lower alkyl)carbamoyl, R.sup.2 is hydrogen, lower alkyl or phenyl, R.sup.3 is hydrogen or lower alkyl, R.sup.4 and R.sup.5 each is hydrogen or R.sup.4 is hydroxy and R.sup.5 is hydrogen or R.sup.4 and R.sup.5 together are a carbon-carbon bond and R.sup.6 is an aryl or N-heteroaryl group carrying a hydroxy group in the 2-position or, in the case of a N-heteroaryl group, also a N-oxide group in the 2-position, and pharmaceutically acceptable acid addition salts of these compounds of formula I which are basic, possess pronounced potassium channel activating activity and can be used as medicaments, particularly in the control or prevention of hypertension, congestive heart failure, angina pectoris, peripheral and cerebral vascular disease and smooth muscle disorders.

  公式的化合物##STR1##，其中R.sup.1是氢、卤素、三氟甲基、硝基、腈、低级烷基、低级烷氧基羰基、低级烷基硫醚、低级烷基亚磺酰基、低级烷氧基、芳酰基、氨基甲酰基、单（低级烷基）氨基甲酰基或二（低级烷基）氨基甲酰基，R.sup.2是氢、低级烷基或苯基，R.sup.3是氢或低级烷基，R.sup.4和R.sup.5各自是氢或R.sup.4是羟基且R.sup.5是氢或R.sup.4和R.sup.5一起是碳-碳键，R.sup.6是一个在2-位带有羟基的芳香族或N-杂芳族基团，或者在N-杂芳族基团的情况下，还在2-位带有N-氧化物基团，以及这些公式I的化合物的药用可接受的酸加成盐，它们是碱性的，具有显著地激活钾通道的活性，可以用作药物，特别是在控制或预防高血压、充血性心力衰竭、心绞痛、外周和脑血管疾病以及平滑肌障碍中。
• [EN] ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS<br/>[FR] COMPOSÉS ÉTHER D'ARYLE ET ÉTHER D'HÉTÉROARYLE EN TANT QUE MODULATEURS DE ROR GAMMA
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2015159233A1

  公开（公告）日：2015-10-22

  The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R2, R3, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

  本公开涉及式(I)的化合物及其药用盐，其中环A、环B、R、R2、R3、n和p如本文所定义，这些化合物作为视黄酸相关孤儿受体γt（RORγt）的调节剂具有活性。这些化合物可以预防、抑制或抑制RORγt的作用，因此在治疗RORγt介导的疾病、疾病、综合症或症状方面具有用处，例如疼痛、炎症、慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、结肠炎、多发性硬化、牛皮癣、神经退行性疾病和癌症。
• Copper-Catalyzed Intramolecular Carbotrifluoromethylation of Alkynes for the Construction of Trifluoromethylated Heterocycles
  作者：Yanan Wang、Min Jiang、Jin-Tao Liu

  DOI：10.1002/chem.201404386

  日期：2014.11.17

  A mild and efficient copper‐catalyzed intramolecular carbotrifluoromethylation of alkynes has been achieved in the presence of Togni reagent as trifluoromethylating reagent. The reaction tolerates a range of substrates to give a group of trifluoromethylated heterocycles with high selectivities. A plausible mechanism was proposed on the basis of experimental results.

  在存在作为三氟甲基化试剂的Togni试剂的情况下，已实现了温和有效的铜催化炔烃分子内碳三氟甲基化反应。该反应容许一定范围的底物，以产生具有高选择性的一组三氟甲基化的杂环。根据实验结果提出了一个合理的机制。
• Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols
  作者：John M. Evans、Charles S. Fake、Thomas C. Hamilton、Robert H. Poyser、Eric A. Watts

  DOI：10.1021/jm00365a007

  日期：1983.11

  position. Exceptions to this were the 7-nitro-4-pyrrolidine analogue and the 6-nitro-3-chloropropylamine, which retained marked antihypertensive activity. All of these compounds were direct vasodilators and had comparable antihypertensive activity to hydralazine and to the calcium antagonist, nifedipine. The synthetic route to these compounds involves cyclization of of propargyl ethers to 2H-1-benzopyrans

  制备了一系列新型取代的反式-4-氨基-3,4-二氢-2,2-二甲基-2H-1-苯并吡喃-3-醇，并在有意识的乙酸脱氧皮质酮（DOCA）/盐水处理中测试了其降压活性。高血压大鼠。最佳的降血压活性需要一个强的吸电子基团与6位上的吡咯烷基或哌啶子基团一起进行6位取代。7-硝基-4-吡咯烷类似物和6-硝基-3-氯丙胺的例外，它们保留了明显的降压活性。所有这些化合物都是直接的血管扩张药，并且具有与肼屈嗪和钙拮抗剂硝苯地平相当的降压活性。这些化合物的合成路线包括将炔丙基醚环化为2H-1-苯并吡喃，然后通过溴代醇转化为3,4-环氧化物，用适当的胺开环。间取代的炔丙基醚在热环化反应中同时产生5-和7-取代的苯并吡喃，前者占优势。描述了一种新的制备2，2-二甲基-7-硝基苯并吡喃的途径。
• Probing the stereoselectivity of P-glycoprotein—synthesis, biological activity and ligand docking studies of a set of enantiopure benzopyrano[3,4-b][1,4]oxazines
  作者：Ishrat Jabeen、Penpun Wetwitayaklung、Freya Klepsch、Zahida Parveen、Peter Chiba、Gerhard F. Ecker

  DOI：10.1039/c0cc03075a

  日期：——

  A series of enantiomerically pure benzopyrano[3,4-b][1,4]oxazines have been synthesised and tested for their ability to inhibit P-glycoprotein. Reducing the conformational flexibility of the molecules leads to remarkable differences in the activity of diastereoisomers. Docking studies into a homology model of human P-gp provide first insights into potential binding areas for these compounds.

  已经合成了一系列对映体纯的苯并吡喃并[3,4-b][1,4]恶嗪，并测试了它们抑制P-糖蛋白的能力。降低分子的构象灵活性会导致非对映异构体活性的显着差异。对人类 P-gp 同源模型的对接研究为这些化合物的潜在结合区域提供了初步见解。